Immunohistochemical analysis of Ki-67, p21waf1/cip1 and apoptosis in marker lesions from patients with superficial bladder tumours treated with vinorelbine intravesical therapy in a preliminary phase I trial

BJU International

Volumn 88, Issue 4, 2001, Pages 425-431

  Bonfil, R D ^a   Gonzalez, A D ^a   Siguelboim, D ^a   Cuello Carrion, F D ^a   Ciocca, D R ^a   Villaronga, A ^a   Metz, L ^a   Mosso, F ^a   Fayad, E ^a   Reale, M ^a   Schmilovich, A J ^a  

^a Centre de Estudios Farmacologicos y Botanicos   (Argentina)

Author keywords

Bladder neoplasms; Chemotherapy; Vinorelbine

Indexed keywords

ANTINEOPLASTIC AGENT; KI 67 ANTIGEN; NAVELBINE; PARAFFIN; PROTEIN P21; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER TUMOR; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INSTILLATION; DRUG RESPONSE; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERFICIAL CANCER; TECHNIQUE; TISSUE SECTION; TUMOR BIOPSY;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BIOPSY; CARCINOMA, TRANSITIONAL CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 0035690228     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2001.02340.x     Document Type: Article

References (25)

1. Cancer of the bladder
2. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients
3. Vinorelbine tartrate (Navelbine): Drug profile and nursing implications of a new vinca alkaloid
4. Vinorelbine induces apoptosis and caspase-3 (CPP.32) expression in leukemia and lymphoma cells: A comparison with vincristine
5. Caspase-8 activation independent of CD95/ CD95-L interaction during paclitaxel-induced apoptosis in human colon cancer cells (HT29-D4)
6. Exposure to vinorelbine inhibits in vitro proliferation and invasiveness of transitional cell bladder carcinoma
7. Intravesical therapy with vinorelbine tartrate: Antitumor activity in orthotopic murine cell carcinoma of the bladder
8. Cell cycling in bladder carcinoma determined by monoclonal antibody
9. Prognostic value of Ki-67 antigen and p53 in urinary bladder cancer: Immunohistochemical analysis of radical cystectomy specimens
10. The prevalence of bcl-2, p53, and ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates
11. p53 and RB expression predict progression in T1 bladder cancer
12. WAF1/CIP1 expression on tumor progression in bladder cancer
13. Apoptosis in carcinoma of the bladder: Relation with radiation treatment results
14. Apoptosis and its clinical signi(r)cance for bladder cancer therapy
15. Phase I clinical trials
16. The World Health Organization International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder
17. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
18. Improved detection of apoptotic cells using a modified in situ TUNEL technique
19. Methodologic guidelines for reports of clinical trials
20. Induction of WAF1/CIP1 by a p53-independent pathway
21. Waf1/Cip1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites
22. Pharmamanual: A comprehensive guide to therapeutic use for methotrexate
23. Mytomicin C therapy in superficial bladder cancer
24. Intravesical instillation of adriamycin in treatment of bladder cancer. A review
25. First line chemotherapy of superficial bladder cancer: Mitomycin vs. thiotepa